NTI’s two clinical trial results are in – Treatment success for BOTH Autism AND for Rett Syndrome

Today, our biotech Investment Neurotech International (ASX: NTI) announced that BOTH of its clinical trials for Autism Spectrum Disorder (ASD) and Rett Syndrome had met the trials’ primary endpoints.


  • No comments yet.
  • Add a comment